Tag Archives: Dr. Reddy’s Laboratories

June, 2018

• 15 June

  Dr. Reddy’s Laboratories Announces FDA Final Approval and Launch of Buprenorphine and Naloxone Sublingual Film

  

  HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has received final approval from the U.S. Food and Drug Administration (USFDA) and is launching Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 …

  Share

  • Facebook
  • Twitter
  • LinkedIn

March, 2016

• 28 March

  Dr. Reddy’s Gains US Rights to XenoPort’s Psoriasis Candidate XP23829

  

  HYDERABAD, India & SANTA CLARA, Calif.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and XenoPort, Inc. (NASDAQ: XNPT) announced today that they have entered into a license agreement pursuant to which Dr. Reddy’s Laboratories will be granted exclusive U.S. rights for the development and commercialization of XenoPort’s clinical-stage …

  Share

  • Facebook
  • Twitter
  • LinkedIn